New study aims to predict cancer risk in NF1 patients before it strikes
NCT ID NCT05677594
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 80 people with Neurofibromatosis type 1 (NF1) who are at high risk for developing malignant peripheral nerve sheath tumors (MPNST). Researchers will use yearly whole-body MRI scans, blood samples, and checkups to track changes in nerve lesions over time. The goal is to find imaging or genetic clues that could predict which patients are most likely to develop cancer, so doctors can catch it earlier.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATYPICAL NEUROFIBROMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Johns Hopkins University
Baltimore, Maryland, 21287, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug combo stop nerve tumors from turning cancerous?
- Light-Activated cream could slow growth of NF1 skin tumors
- Antioxidant drug shows promise for kids with NF1
- New drug combo shows promise for rare nerve tumors
- Could a common supplement help kids with NF1 learn and move better?
- New drug combo aims to tame rare childhood leukemia